Orchard Therapeutics Company
Orchard Therapeutics is a biotechnology company that develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. The company is dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Investors
Founded Date:
2015
Last Funding Type:
Series C
Headquarters:
London, England, United Kingdom
Investors Number:
24
Technology:
Others
Employee Number:
51-100
Industry:
Gene Therapy
Estimated Revenue:
$1M to $10M
Number Of Exists:
Series C
Funding Status:
IPO
Investor Type:
Company
Investment Stage:
N/A
Total Funding:
$310.5M